DUBLIN, Oct. 29, 2026 (GLOBE NEWSWIRE) -- Davion Healthcare Plc (NASDAQ: DAVI) (“Davion” or the “Group”), a developer of non-invasive health monitoring technologies, announces that it has entered into an agreement dated 27 October 2026 to acquire Healthcare Stat Homecare Inc. (“HSH”), a Pennsylvania-incorporated provider of home healthcare services based in Philadelphia..

都柏林，2026年10月29日（环球电讯社）——非侵入式健康监测技术开发商Davion Healthcare Plc（纳斯达克股票代码：DAVI）（“Davion”或“集团”）宣布，公司已签署一份日期为2026年10月27日的协议，收购总部位于费城、在宾夕法尼亚州注册的家庭医疗服务提供商Healthcare Stat Homecare Inc.（“HSH”）。

The total consideration is $13.5 million, comprising $8 million in cash and $5.5 million in Davion shares issued at an agreed value of $13 per share. Completion is expected on or before 31 December 2026, subject to the terms of the acquisition agreement.

总对价为1,350万美元，包括800万美元现金以及按每股13美元的约定价值发行的550万美元Davion股份。预计交易将于2026年12月31日或之前完成，具体取决于收购协议的条款。

HSH is an established, revenue-generating and profitable healthcare services business. For the year ended 31 December 2025, HSH reported gross receipts of approximately $11.6 million and ordinary business income of approximately $1.9 million (unaudited). The acquisition is expected to provide Davion with an established operating business and an additional source of revenue and earnings following completion..

HSH 是一家成熟、创收且盈利的医疗保健服务企业。截至 2025 年 12 月 31 日止年度，HSH 报告的总收入约为 1,160 万美元，普通业务收入约为 190 万美元（未经审计）。预计此次收购将在完成后为 Davion 提供一家成熟的运营企业，并带来额外的收入和收益来源。

The proposed acquisition represents the first in a planned programme of acquisitions of established, revenue-generating and profitable healthcare businesses over the coming year. This strategy is intended to complement Davion’s existing portfolio of proprietary healthcare technologies, broaden its commercial operations and build a more diversified healthcare group..

此次拟议收购是计划在未来一年内对成熟、创收且盈利的医疗保健企业进行一系列收购中的首项。该战略旨在补充 Davion 现有的专有医疗保健技术组合，拓展其商业运营，并构建一个更加多元化的医疗保健集团。

HSH provides skilled nursing, home health aide and rehabilitation services to patients in Philadelphia and surrounding areas. Its clinical programmes include wound care, lymphedema management, dementia and diabetes care, telehealth and rehabilitation. Its workforce includes registered nurses, licensed practical nurses, home health aides, physical and occupational therapists and social workers..

HSH 为费城及周边地区的患者提供专业护理、家庭健康助理和康复服务。其临床项目包括伤口护理、淋巴水肿管理、痴呆症和糖尿病护理、远程医疗以及康复服务。其员工队伍包括注册护士、执业护士、家庭健康助理、物理治疗师、职业治疗师和社会工作者。

HSH provides care to patients of all ages, from children to the elderly, helping individuals remain in their own homes rather than requiring residential or institutional care. According to its website, HSH holds JCAHO accreditation and Medicare and Medicaid certifications, is fully insured and bonded, and accepts major insurance plans..

HSH为各年龄段的患者提供护理，从儿童到老年人，帮助个人留在自己家中，而无需接受住宿式或机构式护理。根据其网站信息，HSH拥有联合委员会（JCAHO）认证以及医疗保险（Medicare）和医疗补助（Medicaid）资格认证，具备完整的保险和担保，并接受主要保险计划。

The acquisition would also extend Davion’s activities beyond the development and commercialisation of healthcare products into the delivery of care in patients’ homes. It could provide opportunities to evaluate the use of Davion’s non-invasive monitoring technologies in home healthcare, including wound monitoring and preventative care.

此次收购还将把达维恩的业务从医疗保健产品的开发与商业化扩展至患者居家护理服务领域。这将为评估达维恩的非侵入性监测技术在居家医疗中的应用提供机会，包括伤口监测和预防性护理。

Any integration or deployment plans will be developed following completion..

任何集成或部署计划将在完成后制定。

Glenn Williams, Chief Executive Officer of Davion, commented:

Davion首席执行官格伦·威廉姆斯评论道：

“HSH is an established and profitable business that will bring meaningful revenues and earnings to Davion, while giving us a direct presence in home healthcare and opportunities to introduce our monitoring and diagnostic technologies closer to patients. Importantly, this is the first in a planned programme of acquisitions of revenue-generating, profitable healthcare businesses over the coming year, as we look to build a broader and more diversified Group combining our proprietary technologies with established operating businesses.

“HSH 是一家成熟且盈利的企业，将为 Davion 带来可观的收入和收益，同时使我们直接涉足家庭医疗保健领域，并为我们提供将监测和诊断技术更贴近患者的机会。重要的是，这是我们在未来一年内计划收购一系列能产生收入且盈利的医疗保健企业的首笔交易，旨在构建一个更广泛、更多元化的集团，将我们的专有技术与成熟的运营业务相结合。”

We look forward to working with HSH’s management to support its existing operations and explore opportunities to integrate our technologies into the delivery of care at home.”.

我们期待与HSH的管理层合作，支持其现有运营，并探索将我们的技术整合到居家护理服务中的机会。

Manilal Mathai, Co-owner and Chief Executive Officer of HSH, added:

HSH 的联合所有者兼首席执行官马尼拉尔·马泰补充道：

“We share Davion’s commitment to improving care for patients outside hospital settings. Joining forces would give us an opportunity to combine HSH’s home healthcare experience with Davion’s technology-led approach, while continuing to focus on the quality and continuity of care we provide to patients and families.”.

“我们认同 Davion 致力于改善医院外患者护理的承诺。携手合作将使我们有机会把 HSH 的居家医疗经验与 Davion 以技术为主导的方法相结合，同时继续专注于为患者和家庭提供高质量、连续性的护理服务。”

Media Enquiries

媒体垂询

Rosewood Communications

罗斯伍德通信

+44 (0) 20 7653 8702

+44 (0) 20 7653 8702

davion@rosewoodpr.co.uk

davion@rosewoodpr.co.uk

Investor Relations Inquiries

投资者关系咨询

Mark Komonoski

马克·科莫诺斯基

Partner

合作伙伴

Integrous Communications

诚信通讯

Toll Free: 877-255-8483

免费电话：877-255-8483

Mobile: 403-470-8384

手机：403-470-8384

About Davion Healthcare Plc

关于 Davion Healthcare Plc

Davion Healthcare Plc is a next-generation digital healthcare company developing proprietary, non-invasive health monitoring technologies designed to support the early identification of medical anomalies outside traditional clinical environments.

Davion Healthcare Plc 是一家下一代数字医疗公司，正在开发专有的非侵入式健康监测技术，旨在支持在传统临床环境之外早期识别医学异常。

The Company’s flagship product, BreastCheck, is an FDA-registered at-home breast health screening test designed to identify potential abnormalities through changes in breast temperature. Davion’s broader portfolio includes technologies addressing circulation and foot health, testicular health, skin anomalies, wound monitoring, blood pressure and other areas of preventive healthcare..

公司的旗舰产品 BreastCheck 是一款已在 FDA 注册的居家乳房健康筛查测试，旨在通过监测乳房温度变化来识别潜在异常。Davion 的更广泛产品组合包括针对血液循环与足部健康、睾丸健康、皮肤异常、伤口监测、血压以及其他预防性医疗保健领域的技术。

Davion’s growth strategy combines the development and commercialisation of its proprietary technologies with complementary acquisitions intended to expand the Group’s product portfolio and commercial, manufacturing and distribution capabilities.

Davion 的增长战略结合了其专有技术的开发与商业化，以及旨在扩大集团产品组合和商业、制造和分销能力的互补性收购。

Further information is available at

更多信息请访问

www.davionhealthcare.com

www.davionhealthcare.com

.

。

Forward-Looking Statements

前瞻性陈述

This announcement contains forward-looking statements within the meaning of the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, those identified by words such as “believes,” “will,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “targets,” “projects” and similar expressions..

本公告包含1995年美国《私人证券诉讼改革法》“安全港”条款所定义的前瞻性陈述。此类陈述包括但不限于使用“相信”、“将”、“预期”、“预计”、“估计”、“打算”、“计划”、“目标”、“规划”等词语以及类似表述所识别的陈述。

The statements in this release are based upon the current beliefs and expectations of the Company’s management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in these forward-looking statements.

本新闻稿中的陈述基于公司管理层当前的信念和预期，并受到重大风险和不确定性的影响。实际结果可能与这些前瞻性陈述中所述的结果存在差异。

Numerous factors could cause or contribute to such differences, including, but not limited to, the results of product evaluations, studies, regulatory reviews and commercial adoption and/or other studies, clinical trials, the challenges inherent in new product development initiatives, the impact of any competitive products, the Company’s ability to license and protect its intellectual property, its ability to raise additional capital in the future, changes in government policy and/or regulation, potential litigation by or against the Company, any governmental review of its products or practices, and other risks discussed from time to time in the Company’s filings with the Securities and Exchange Commission..

众多因素可能导致或促成此类差异，包括但不限于：产品评估结果、研究、监管审查及商业化采纳情况和/或其他研究、临床试验、新产品开发计划固有的挑战、任何竞争性产品的冲击、公司许可和保护其知识产权的能力、未来筹集额外资本的能力、政府政策和/或法规的变化、针对公司或由公司提起的潜在诉讼、政府对其产品或实践的任何审查，以及公司在向美国证券交易委员会提交的文件中不时讨论的其他风险。

The Company undertakes no obligation to update any forward-looking statements, or any information contained in this press release or in other public disclosures, at any time, except as required by applicable law.

除适用法律要求外，本公司不承担任何义务在任何时候更新任何前瞻性陈述或本新闻稿及其他公开披露中包含的任何信息。

The investing public is reminded that only announcements or information about Davion Healthcare Plc disseminated by the Company and bearing its name are considered official.

提醒广大投资者，只有由达维恩医疗有限公司（Davion Healthcare Plc）发布并署名的公告或信息才被视为官方信息。